The discovery and potential of N-sulfonylated dipeptide VLA-4 antagonists

Current Topics in Medicinal Chemistry

Volumn 4, Issue 14, 2004, Pages 1461-1471

  Hagmann, William K ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 AMINOBENZOTRIAZOLE; ALANINE DERIVATIVE; ALPHA4 INTEGRIN; AMINO ACID DERIVATIVE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA7 INTEGRIN; BIO 1211; CARBOXYLIC ACID DERIVATIVE; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN A; CYTOCHROME P450 3A4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MONOCARBOXYLATE TRANSPORTER; MULTIDRUG RESISTANCE PROTEIN 2; NATALIZUMAB; PHENYLALANINE DERIVATIVE; TETRAHYDROFURAN DERIVATIVE; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4;

ASTHMA; CELL TRANSPORT; CLINICAL TRIAL; COMBINATORIAL LIBRARY; DRUG BINDING SITE; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME SUBSTRATE; EOSINOPHIL; HUMAN; LUNG; NONHUMAN; PLASMA CLEARANCE; PLASMA PROTEIN BINDING; PROCESS OPTIMIZATION; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; DIPEPTIDES; HUMANS; INHIBITORY CONCENTRATION 50; INTEGRIN ALPHA4BETA1; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES;

EID: 4844227887     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043387557     Document Type: Review

References (47)

1. Adams, S. P.; Lobb, R. R. Inhibitors of Integrin Alpha 4 Beta 1 (VLA-4). In Ann. Rep. Med. Chem.; Doherty, A. M.; Ed.; Academic Press: New York, 1999; pp. 179-188.
2. Porter, J. R. Novel VLA-4 Antagonists. Drugs, 2000, 3, 788-798.
3. Tilley, J. W.; Sidduri, A. VLA-4 Antagonists. Drugs of the Future, 2001, 26, 985-998.
4. Tilley, J. W. VLA-4 Antagonists. Expert Opin. Thera. Pat. 2002, 12, 991-1008.
5. Jackson, D. Y. Alpha-4 Integrin Antagonists. Curr. Pharm. Des. 2002, 8, 1229-1253.
6. Holland, G. W.; Biediger, R. J.; Vanderslice, P. Antagonists of VLA-4. In Ann. Rep. Med. Chem.; Doherty, A. M.; Ed.; Academic Press: New York, 2002; pp. 65-74.
7. Wang, J. H.; Pepinsky, R. B.; Stehle, T.; Liu, J. H.; Karpusas, M.; Browning, B.; Osborn, L. The Crystal Structure of an N-Terminal Two-Domain Fragment of Vascular Cell Adhesion Molecule 1 (VCAM-1): A Cyclic Peptide Based on the Domain 1 C-D Loop can Inhibit VCAM-1/ VLA-4 Integrin. Proc. Natl. Acad. Sci. U.S.A., 1995, 92, 5714-5718
8. Komoriya, A.; Green, L. J.; Mervic, M.; Yamada, S. S.; Yamada, K. M.; Humphries, M. J. The minimal essential sequence for a major cell type-specific adhesion site (CS1) within the alternatively spliced type III connecting segment domain of fibronectin is leucine-aspartic acid-valine. J. Biol. Chem. 1991, 266, 15075-15079.
9. 5CO), a novel, selective, cyclic peptide inhibitor of VLA-4-mediated cell adhesion. Brit. J. Pharmacol. 1999, 126, 1751-1760.
10. Hagmann, W. K. ; Durette, P. L; Lanza, T. J; Kevin, N J; DeLaszlo, S. E.; Kopka, I. E; Young, D. N.; Magriotis, P. A.; Li, B.; Lin, L. S.; Yang, G. X.-Q.; Kamenecka, T.; Chang, L. L; Wilson, J.; MacCoss, M.; Mills, S. G; Van Riper, G.; McCauley, W. D.; Egger, L. A; Kidambi, U.; Lyons, K. A.; Vincent, S. H; Stearns, R. A; Colletti, A. E.; Teffera, Y.; Tong,X.; J. Fenyk-Melody; Owens, K. A; Levorse, D. A; Kim, P.; Schmidt, J. A.; Mumford, R. A. The Discovery of Sulfonylated Dipeptides as Potent VLA-4 Antagonists. Bioorg. Med. Chem. Lett. 2001, 11, 2709-2713.
11. Head, J. C.; Archibald, S. C.; Warrellow, G. J.; Porter, J. R. Preparation of Phenylalanine Derivatives Having VLA-4 Antagonistic Activity. PCT Pat. Apl. WO99/61465, Dec. 2, 1999.
12. Semko, C. M.; Dressen, D. B.; Grant, F. S.; Konradi, A. W.; Pleiss, M. A.; Thorsett, E. D.; Freedman, S. B.; Holsztynska, E. J.; Quinn, K. P.; Yednock, T. Development of CT757: A Potent and Highly Selective Small Molecule Inhibitor of VLA-4. Abstracts of Papers, Part 2, 220th National Meeting of the American Chemical Society, Washington, DC; American Chemical Society: Washington, DC, 2000; Abstract MEDI 133.
13. Furth, P. S.; Chiang, S. L.; Sircar, I.; Griffith, R. C.; Nowlin, D.; Gorscan, F. S.; Mah, J.; Lazarides, E. Parallel-synthesis Optimization of TR-14035 a Dual Active α4β7/α4β1 Integrin Antagonist: Generation of α4β1 Selective Antagonists. Abstracts of Papers, Part 1, 218th National Meeting of the American Chemical Society, New Orleans, LA; American Chemical Society: Washington, DC, 1999; Abstract MEDI 61.
14. Chang, L. L.; Truong, Q.; Mumford, R. A.; Egger, L. A.; Kidambi, U.; Lyons, K.; McCauley, E.; Van Riper, G.; Vincent, S.; Schmidt, J. A.; MacCoss, M.; Hagmann, W. K. The Discovery of Small Molecule Carbamates as Potent Dual α4β1/α4β7 Integrin Antagonists. Bioorg. Med. Chem. Left. 2002, 12, 159-163.
15. Kopka, I. E.; Young, D.; Lin, L. S.; Mumford, R. A.; MacCoss, M.; Mills, S. G.; Van Riper, G.; McCauley, E.; Egger, L.; Kidambi, U.; Schmidt, J. A.; Lyons, K.; Stearns, R.; Vincent, S.; Colletti, A.; Wang, Z.; Tong, S.; Wang, J.; Zheng, S.; Owens, K.; Levorse, D.; Hagmann, W. K. Substituted N-(3,5-dichlorobenzenesulfonyl)-L-Prolyl-phenylalanine Analogues as Potent VLA-4 Antagonists. Bioorg. Med. Chem. Lett. 2002, 12, 637-640.
16. Chen, L.; Tilley, J. W.; Huang, T.-N.; Miklowski, D., Trilles, R.; Guthrie, R. W.; Luk, K.; Hanglow, A.; Rowan, K.; Schwinge, V.; Wolitzky, B. N-Acyl Phenylalanine Analogues as Potent Small Molecule VLA-4 Antagonists. Bioorg. Med. Chem. Lett. 2000, 10, 725-727;
17. Chen, Li; Tilley, Jefferson; Trilles, Richard V.; Yun, Weiya; Fry, David; Cook, Charles; Rowan, Karen; Schwinge, Virginia; Campbell, Robert N-Acyl-L-phenylalanine derivatives as potent VLA-4 antagonists that mimic a cyclic peptide conformation. Bioorg. Med. Chem. Lett. 2002, 12, 137-140.
18. Archibald, S. C.; Head, J. C.; Gozzard, N.; Howat, D. W.; Parton, T. A. H.; Porter, J. R.; Robinson, M. K.; Shock, A.; Warrellow, G. J.; Abraham, W. M. Discovery and Evalulation of Potent, Tyrosine-based α4β1 Integrin Antagonists. Bioorg. Med. Chem. Lett. 2000, 10, 997-999.
19. Porter, J. R.; Archibald, S. C.; Brown, J. A.; Childs, K.; Critchley, D.; Head, J. C.; Hutchinson, B.; Parton, T. A. H.; Robinson, M. K.; Shock, A.; Warrellow, G. J.; Zomaya, A. Discovery and Evaluation of N-(triazin-1,3,5-yl) Phenylalanine Derivatives as VLA-4 Integrin Antagonists. Bioorg. Med. Chem. Lett. 2000, 10, 1591-1594.
20. Abraham, W. M.; Ashfaq, A.; Sielczak, M. W.; Narita, M.; Arrhenius, T.; Elices, M. J. Blockade of Late-phase Airway Response and Airway Hyperresponsiveness in Allergic Sheep with a Small Molecule Peptide Inhibitor of VLA-4. Am. J. Respir. Crit. Care Med. 1997, 156, 696-703.
21. Lin, L. S.; Kopka, I.; Mumford, R. A.; Magriotis, P. A.; Lanza Jr., T.; Durette, P. L.; Kamenecka, T.; Young, D. N.; de Laszlo; S.; Van Riper, G.; Kidambi, U.; Egger, L. A.; Tong, X.; Lyons, K.; Vincent, S.; Stearns, R.; Colletti, A.; Teffera, J.; Fenyk-Melody, J.; Schmidt, J. A.; MacCoss, M.; Hagmann, W, K.The Discovery of Acylated β-Amino Acid as Potent and Orally Bioavailable VLA-4 Antagonists Bioorg. Med. Chem. Lett. 2002, 12, 611-614.
22. Kopka, I. E.; Young, D.; Lin, L. S., Mumford, R. A.; MacCoss, M.; Mills, S. G.; Van Riper, G.; McCauley, E.; Egger, L.; Kidambi, U.; Schmidt, J. A.; Lyons, K.; Stearns, R.; Vincent, S.; Colletti, A.; Wang, Z.; Tong, S.; Wang, J.; Zheng, S.; Owens, K.; Levorse, D.; Hagmann, W. K. Substituted N-(3,5-Dichlorobenzene sulfonyl)-L-Prolyl Phenylalanine Analogues as Potent VLA-4 Antagonists. Bioorg. Med. Chem. Lett. 2002, 12, 2415-2418.
23. Lin, L. S.; Lanza, T.; McCauley, E.; Van Riper, G.; Kidambi, U.; Cao, J.; Egger, L. A.; Mumford, R. A.; Schmidt, J. A.; Hagmann, W. K. Specific and Dual Antagonists of α4β1 and α4β7 Integrins. Bioorg. Med. Chem. Lett. 2002, 12, 133-136.
24. DeLaszlo, S. E.; Li, B.; McCauley, E.; Van Riper, G.; Hagmann, W. K. Identification of Unique VLA-4 Antagonists from a Combinatorial Library. Bioorg. Med. Chem. Left. 2002, 12, 685-688.
25. Lin, K. C., Ateeq, H.S.; Hsiung, S. H.; Chong, L. T.; Zimmerman, C. N.; Castro, A.; Lee, W.-C.; Hammond, C. E.; Kalkunte, S.; Chen, L.-L.; Pepinsky, R. B.; Leone, D. R.; Sprague, A. G.; Abraham, W. M.; Gill, A.; Lobb, R. R.; Adams, S. P. J. Med. Chem. 1999, 42, 920-934.
26. DeLaszlo, S. E.; Hagmann, W. K. para-Aminomethylaryl-carboxamide derivatives. US 6,191,171, Feb. 2, 2001.
27. Li, B.; deLaszlo, S. E.; Kamenecka, T.; Kopka, I. E.; Durette, P. L.; Lanza, T.; MacCoss, M.; Tong, S.; Mumford, R. A.; McCauley, E.; Van Riper, G.; Schmidt, J. A; Hagmann, W. K. N-(Arylacetyl)-biphenylalanines as Potent VLA-4 Antagonists. Bioorg. Med. Chem. Lett. 2002, 12, 2141-2144.
28. Gutteridge, C. E.; DeLaszlo, S. E.; Kamenecka, T. M.; McCauley, E.; Van Riper, G.; Mumford, R. A.; Kidambi, U.; Egger, L. A.; Tong, S.; Hagmann, W. K. N-(3-Phenylsulfonyl-3-piperonyl)-Phenylalanine Derivatives as Potent, Selective VLA-4 Antagonists. Bioorg. Med. Chem. Lett. 2003, 13, 885-890.
29. 1 integrin antagonist. Bioorg. Med. Chem. 2002, 10, 2051-2066.
30. Yang, G. X.; Chang, L. L.; Truong, Q.; Doherty, G. A.; Magriotis, P. A.; deLaszlo, S. E.; Li, B.; MacCoss, M.; Kidambi, U.; Egger, L. A.; McCauley, E.; Van Riper, G.; Mumford, R. A.; Schmidt, J. A.; Hagmann, W. K. N-Tetrahydrofuroyl-(L)-phenylalanine derivatives as potent VLA-4 antagonists. Bioorg. Med. Chem. Lett. 2002, 12, 1497-1500.
31. Doherty, G. A.; Yang, G. X.; Borges, E.; Chang, L. L.; MacCoss, M.; Tong, S.; Kidambi, U.; Egger, L. A.; McCauley, E.; Van Riper, G.; Mumford, R. A.; Schmidt, J. A.; Hagmann, W. K. Substituted tetrahydrofuroyl-1-phenylalanine derivatives as potent and specific VLA-4 antagonists. Bioorg. Med. Chem. Lett. 2002, 12, 1501-1505.
32. Kamenecka, T. M.; Lanza, T.; deLaszlo, S. E.; Li, B.; McCauley, E. D.; Van Riper, G.; Egger, L. A.; Kidambi, U.; Mumford, R. A.; Tong, S.; MacCoss, M.; Schmidt, J. A.; Hagmann, W. K. N-Arylprolyl-dipeptides as Potent VLA-4 Antagonists. Bioorg. Med. Chem. Lett. 2002, 12, 2205-2208.
33. Doherty, G. A. ; Kamenecka, T. M.; McCauley, E. D.; Van Riper, G.; Mumford, R. A; Tong, S.; Hagmann, W. K. N-aryl phenylalanine analogues as VLA-4 antagonists. Bioorg. Med. Chem. Lett. 2002, 12, 729-731.
34. Head, J. C.; Porter, J. R.; Warrellow, G. J.; Archibald, S. C.; Hutchinson, B. W. Phenylalanine Derivatives as Alpha 4 Integrin Inhibitors. PCT Pat. Appl. WO00/18759, 6 April 2000.
35. Porter, J. R.; Archibald, S. C.; Brown, J. A.; Childs, K.; Critchley, D.; Head, J. C.; Hutchinson, B.; Parton, T. A. H.; Robinson, M. K.; Shock, A.; Warrellow, G. J.; Zomaya, A. N-(Pyrimidin-4-yl) and N-(Pyridin-2-yl) Phenylalanine Derivatives as VLA-4 Integrin Antagonists. Bioorg. Med. Chem. Lett. 2002, 12, 1595-1598.
36. Tang, W.; Sterns, R., unpublished results.
37. Yu, N. X.; Raab, C. E.; Dean, D. C.; Lin, L. S.; Melillo, D. G. unpublished results.
38. Mathews, J. M.; Dostal, L. A.; Bend, J. R. Inactivation of rabbit pulmonary cytochrome P 450 in microsomes and isolated perfused lungs by the suicide substrate 1-aminobenzotriazole. J. Pharmacol. Exp. Ther. 1985, 235, 186-190.
39. Evers, R.; Zaman, G. J. R.; Van Deetmer, L.; Jansen, H.; Calafat, J.; Oomen, L. C. J. M.; Oude Elferink, R. P. J.; Borst, P.; Schinkel, A. H. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J. Clin. Invest. 1996, 97, 1211-1218.
40. Schinkel, A. H.; Mayer, U.; Wagenaar, E.; Mol, C. A.; van Deemter, L.; Smit, J. J.; van der Valk, M. A.; Voordouw, A. C.; Spits, H.; van Tellingen, O.; Zijlmans, J. M.; Fibbe, W. E.; Borst, P. Normal viability and altered pharmacokinetics in mice lacking mdrl-type (drug-transporting) P-glycoproteins. Proc. Nat. Acad. Sci. USA 1997, 94, 4028-4033.
41. Kuipers, F.; Enserink, M.; Havinga, R.; van der Steen, A. B.; Hardonk, M. J.; Fevery, J.; Vonk, R. J. Separate transport systems for biliary secretion of sulfated and unsulfated bile acids in the rat. J. Clin. Invest. 1988, 8, 1593-1599.
42. Miller, D. M.; Khan, O. A.; Sheremata, W. A.; Blumhardt, L. D.; Rice, G. P. A.; Libonati, M. A.; Willmer-Hulme, A. J.; Dalton, C. M.; Miszkiel, K. A.; O'Connor, P. W. et al. A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. New Engl. J. Med. 2003, 348, 15-23.
43. Ghosh, S.; Goldin, E.; Gordon, F. H.; Malchow, H. A.; Rask-Madsen, J.; Rutgeerts, P.; Vyhnálek, P.; Zá dorová, Z.; Palmer, T., Donoghue, S.; et al. Natalizumab for Active Crohn's Disease. New Engl. J. Med. 2003, 348, 24-32.
44. Chigaev, A.; Zwartz, G.; Graves, S. W.; Dwyer, D. C.; Tsuji, H.; Foutz, T. D.; Edwards, B. S.; Prossnitz, E. R.; Larson, R. S.; Sklar, L. A. α4β1-Integrin Affinity Changes Govern Cell Adhesion. J. Biol Chem. 2003, in press.
45. Chen, L. L.; Whitty, A.; Scott, D.; Lee, W.-C.; Cornebise, M.; Adams, S. P.; Petter, R. C.; Lobb, R. R.; Pepinsky, R. B. Evidence That Ligand and Metal Ion Binding to Integrin α4β1 Are Regulated through a Coupled Equilibrium. J. Biol. Chem. 2001, 276, 36520-36529.
46. Doherty, G. A.; Yang, G. X.; Borges, E.; Tong, S.; McCauley, E. D.; Treonz, K. M.; Van Riper, G.; Pacholok, S.; Si, Q.; Koo, G. C.; Shah, K.; Mumford, R. A.; Hagmann, W. K. N-Isonicotinoyl-(L)-4-aminophenylalanine Derivatives as Tight Binding VLA-4 Antagonists. Bioorg. Med. Chem. Lett. 2003, 13, 1891-1895.
47. Koo, G. C.; Shah, K.; Ding, G. Y.; Xiao, J.; Wnek, R.; Doherty, G.; Tong, X.-C.; Pepinsky, R. B.; Lin, K.-C.; Hagmann, W. K.; Kawka, D.; Singer, I. A Small Molecule VLA-4 Antagonist Can Inhibit OVA-induced Lung Inflammation. Am. J. Respir. Crit. Care Med., 2003, 167, 1400-1409.